Schizoaffective Disorders Completed Phase 4 Trials for Risperidone (DB00734)

Also known as: Schizoaffective disorder / Schizophrenia schizoaffective / Schizoaffective psychosis / Schizo-affective type schizophrenia

IndicationStatusPhase
DBCOND0033299 (Schizoaffective Disorders)Completed4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02307396Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic PatientsTreatment
NCT00526877An Efficacy and Safety Study of Long-acting Risperidone in Participants With Schizophrenia or Schizoaffective Disorders Who Are Receiving Psychiatric Home Care TreatmentTreatment
NCT00330863Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating EfficacyTreatment
NCT00061802Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective DisorderTreatment
NCT00190749Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective DisorderTreatment
NCT00206102A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective DisorderTreatment
NCT00208143Seroquel Therapy for Substance Use Disorders Comorbid With SchizophreniaTreatment
NCT00253110A Comparison of Risperidone With Haloperidol in Patients With Schizophrenia and Schizoaffective DisorderTreatment
NCT00313391Risperdal Consta and Health Care Utilization in Patients With Schizophrenia
NCT00337662Efficacy Study of Early Onset of Antipsychotic Drug Action in SchizophreniaTreatment
NCT00378183A Study Comparing Three Strategies to Switch Patients With Schizophrenia or Schizoaffective Disorder to Risperidone After Unsuccessful Treatment With Olanzapine.Treatment
NCT00423878Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective DisorderTreatment
NCT00515723Glucose and Lipid Metabolism on Antipsychotic MedicationTreatment
NCT01855074An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective DisordersTreatment